Gentler pre-surgery treatment for HER2-positive early breast cancer
Part of Cancer clinical trials.
This study tests a less intense treatment plan before surgery for people with HER2-positive breast cancer that hasn't spread to lymph nodes. The goal is to see if a milder approach works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer, which means your tumor has a specific protein that helps it grow.
- Your tumor is stage T2N0M0, meaning the tumor is between 2 and 5 cm, hasn't spread to lymph nodes, and hasn't spread to other parts of the body.
- You have not had any chemotherapy, hormone therapy, targeted therapy, or radiation for this breast cancer before.
- You do not have severe or uncontrolled medical conditions that would make chemotherapy unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This trial compares two treatments for women with a specific type of early breast cancer (HER2-positive, medium risk) that hasn't spread. One group gets a newer targeted drug (T-DXd), the other gets standard chemo plus targeted therapy (THP). The goal is to see which works better with fewer side effects.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how your cancer responds, aiming to give you the best possible outcome.
This trial looks at whether Herceptin (trastuzumab) can be used as after-treatment with less chemotherapy for certain early breast cancers. It may help reduce how much chemotherapy you need, while still lowering the chance the cancer comes back.
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.